@AndrearicFili @FordePatrick Agree. This is the design that is needed. All patients should be receiving some form of definitive local control

MDT Bridge from the other side of the coin: 15% of patients and 30% of borderline resectable will never receive surgery. Maintanance post chemo-RT in a 'PACIFIC style' could be not enough considering the previous exposure to ICI in the neoadjuvant setting @AndrearicFili #ESMO25

Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had 2 cycles of durvalumab + chemo then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable. #ESMOAmbassadors

#ESMO25 Highlights of Day 1 Opening session: - 🏆Lifetime Achievement lecture by @RolfStahel🇨🇭a pioneer of clinical research @etop_ibcsg - 🏆@Women4Oncology lecture by Natasha Leighl🇨🇦, a leader in thoracic Onc, liquid biopsy, & mentorship #ESMO25 #ESMOAmbassadors @myESMO

📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy) ⬆️ 12-month PFS rate: 72% vs 54% ⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025) 😳 really not “oligo” population! ✅Grade ≥3 AEs: 29% (LCT arm) vs 22% (control) #radonc

Osimertinib plus local therapy improves PFS in EGFR-mutant NSCLC

New #JITC article: Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial https://t.co/hK5tikToEa @StevenLin_MDPhD @liao_zhongxing @dave_qian

EORTC consensus on resectable stage III NSCLC 105 cases reviewed by 53 🇪🇺 experts. Resectability criteria for trials & practice. A TNM subset was resectable if ≥75% agreed. T1–T4 (size/satellite) w/ N0–N2 single were resectable; N2 multi, bulky/invasive & N3 were unresectable.

Can’t wait for MDT-Bridge results to be public! @DoctorJSpicer @MartinReck2 @Oncology_at_AZ @tssmn #lcsm @GenThorSurgClub @STS_CTsurgery @AATSHQ @UVASurgery @UVACancerCenter

Definition of resectable stage III non-small cell lung cancer (NSCLC) ...

UNREST sIII NSCLC is a new hot topic -PACIFIC remains SoC Efforts to improve but: -Intensification IO consol ❌ -IO with CRT❌ -Promising data with i CTIO—>CRT🔆 Future: *SKS03❓ *Borderline unresect —> Resect: MDT Bridge❓ (ESMO) *Lots of challenges ✳️ https://t.co/5RMwoMQthW

@RManochakian @LungSummit @Alfdoc2 @peters_solange @NReguart @tnewsomdavis @Tony_Calles @TommyJohn00 @FordePatrick @MdCurioni @LeXiuning @AndrearicFili We would like to inform you that your post has been published on https://t.co/igx4msE1Ge. Thank you for sharing. https://t.co/EAkwFr5BKw

📢Out now in @jitcancer! Global Pembro-5Y registry (61 centers, 14 countries) + advanced stats & AI 👇 1) In modern day oncology (1/4 patients alive at 5y) Prognosis is dynamic, not static 2) AI reveals time-dependent complexity 3) Comorbidities regain importance over time

I got to learn from my radiation oncology colleagues at #ASTRO25 - had a great #SCLC session with @PercyLeeMD @KHigginsMD @QuynhNguyenMD and happy to see @NitikaPaudel and @AndrearicFili (fresh off his @LungSummit lecture)!

🙏It was an honor to join GREAT friends & global experts to speak about #SmallCell #LungCancer at the: ⭐️2025 #ILCS @LungSummit KUDOS to the amazing chairs & organizing committee on a: ✅VERY #Educational & Interactive meeting with participants from more than 100 countries.

@DrewMoghanaki @CharuAggarwalMD @DoctorJSpicer @HoudaBahig @IsaOpitz @Mat_Guc @finn_corinne @SBroderickMD May need to change the title to “local therapy after chemo-immunotherapy for unresectable locally advanced nsclc” although at this point that has been reported multiple times in prospective trials w encouraging results so it’s getting a bit old… https://t.co/qArmkqrD7o

Happy birthday to Dr. @AndrearicFili - speaking today @LungSummit on radiation strategies for stage III NSCLC. Will induction chemo-IO help further improve outcomes with chemoradiation + durvalumab? Or can we use pharmacodynamic markers like ctDNA in adaptive risk models?

It is time to tailor 1st line treat in NSCLC according to primary/acquired ICI resistance. Our reconstructed IPD analysis (19 RCTs) shows that adding platinum chemo to ICI may 🔼 acquired resistance (+15%) vs mono-ICI & 🔽 duration of response (5-7 mo) https://t.co/wJjwwsp95g

First results of the DEDALUS phase 2 trial presented as a poster at WCLC2025. Induction CT-IO , reduced dose RT, and IO maintenance in pts candidate to sequential CRT. Thanks to all my co-investigators and patients!

Published by @VJOncology